India, June 30 -- Biotechnology company Moderna, Inc. (MRNA) announced Monday positive results from a Phase 3 efficacy study evaluating the relative vaccine efficacy (rVE) against influenza illness of mRNA-1010, the Company's seasonal influenza (flu) vaccine candidate, compared to a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older.
mRNA-1010 demonstrated superior rVE of 26.6% higher than a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older in the overall study population.
Additionally, strong rVE was observed for each influenza strain contained in the vaccine, including A/H1N1 rVE of 29.6%), A/H3N2 rVE of 22.2%), and the B/Victoria lineages rVE of29.1%.
Subgroup analyses...